MA30006B1 - Composes anti-hypercholesterolemiques - Google Patents

Composes anti-hypercholesterolemiques

Info

Publication number
MA30006B1
MA30006B1 MA30894A MA30894A MA30006B1 MA 30006 B1 MA30006 B1 MA 30006B1 MA 30894 A MA30894 A MA 30894A MA 30894 A MA30894 A MA 30894A MA 30006 B1 MA30006 B1 MA 30006B1
Authority
MA
Morocco
Prior art keywords
compounds
cholesterol
hypercholesterolemic compounds
hypercholesterolemic
esters
Prior art date
Application number
MA30894A
Other languages
English (en)
Inventor
Robert J Devita
Gregori J Morriello
Peter Lin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA30006B1 publication Critical patent/MA30006B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention fournit des inhibiteurs de l'absorption du cholestérol de formule 1 et les sels pharmaceutiquement acceptables et esters de ceux-là. Les composés sont utiles pour abaisser les niveaux du cholestérol plasmatique, en particulier le LDL-cholestérol, et pour le traitement et la prévention de l'athérosclérose et des événements de la maladie athéroscléreuse.
MA30894A 2005-10-05 2008-05-02 Composes anti-hypercholesterolemiques MA30006B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72378105P 2005-10-05 2005-10-05

Publications (1)

Publication Number Publication Date
MA30006B1 true MA30006B1 (fr) 2008-12-01

Family

ID=37845278

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30894A MA30006B1 (fr) 2005-10-05 2008-05-02 Composes anti-hypercholesterolemiques

Country Status (25)

Country Link
US (2) US20090137546A1 (fr)
EP (1) EP1934175B1 (fr)
JP (1) JP4879991B2 (fr)
KR (1) KR20080050610A (fr)
CN (1) CN101277930A (fr)
AR (1) AR058068A1 (fr)
AT (1) ATE488495T1 (fr)
AU (1) AU2006302584B2 (fr)
BR (1) BRPI0616834A2 (fr)
CA (1) CA2624481C (fr)
CR (1) CR9903A (fr)
DE (1) DE602006018341D1 (fr)
DO (1) DOP2006000211A (fr)
EA (1) EA200801008A1 (fr)
ES (1) ES2354460T3 (fr)
GT (1) GT200600444A (fr)
IL (1) IL190434A0 (fr)
MA (1) MA30006B1 (fr)
NO (1) NO20082075L (fr)
PE (1) PE20070493A1 (fr)
SV (1) SV2009002863A (fr)
TN (1) TNSN08153A1 (fr)
TW (1) TW200806623A (fr)
WO (1) WO2007044318A2 (fr)
ZA (1) ZA200802587B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1699760B1 (fr) * 2003-12-23 2017-05-17 Merck Sharp & Dohme Corp. Composes anti-hypercholesterolemie
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2550215A1 (fr) * 2003-12-23 2005-07-07 Astrazeneca Ab Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010513485A (ja) * 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション 抗高コレステロール血症化合物
DE102009023046B4 (de) 2008-05-30 2016-10-13 Hyundai Motor Company Automatisch schaltbares Getriebe eines Kraftfahrzeuges
WO2010056788A1 (fr) * 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Composés anti-hypercholestérolémiques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ14294A3 (en) * 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MX9606319A (es) * 1994-06-20 1997-05-31 Schering Corp Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
AU1609702A (en) * 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
CN100439361C (zh) * 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1699760B1 (fr) * 2003-12-23 2017-05-17 Merck Sharp & Dohme Corp. Composes anti-hypercholesterolemie
WO2006086562A2 (fr) * 2005-02-09 2006-08-17 Microbia, Inc. Derives de phenylazetidinone
US7696177B2 (en) * 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2009003823A (es) * 2006-11-02 2009-05-11 Sanofi Aventis Deutschland Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas.

Also Published As

Publication number Publication date
US7704988B2 (en) 2010-04-27
WO2007044318A3 (fr) 2007-07-12
DE602006018341D1 (de) 2010-12-30
ES2354460T3 (es) 2011-03-15
WO2007044318A2 (fr) 2007-04-19
EP1934175A2 (fr) 2008-06-25
CN101277930A (zh) 2008-10-01
TW200806623A (en) 2008-02-01
CA2624481C (fr) 2012-04-03
JP4879991B2 (ja) 2012-02-22
CR9903A (es) 2008-07-29
AR058068A1 (es) 2008-01-23
GT200600444A (es) 2007-05-04
KR20080050610A (ko) 2008-06-09
DOP2006000211A (es) 2007-05-31
JP2009511475A (ja) 2009-03-19
PE20070493A1 (es) 2007-06-13
CA2624481A1 (fr) 2007-04-19
NO20082075L (no) 2008-07-04
ZA200802587B (en) 2009-06-24
AU2006302584B2 (en) 2011-10-13
TNSN08153A1 (en) 2009-10-30
SV2009002863A (es) 2009-02-19
AU2006302584A1 (en) 2007-04-19
BRPI0616834A2 (pt) 2016-08-23
US20070078098A1 (en) 2007-04-05
EP1934175B1 (fr) 2010-11-17
IL190434A0 (en) 2008-11-03
US20090137546A1 (en) 2009-05-28
EA200801008A1 (ru) 2009-02-27
ATE488495T1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
MA30006B1 (fr) Composes anti-hypercholesterolemiques
MA29647B1 (fr) Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
MA30412B1 (fr) Composés Pharmaceutiques
MA35285B1 (fr) Indazoles
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
WO2007120647A3 (fr) Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
MA31373B1 (fr) Composes amino-heterocycliques
MXPA06000326A (es) Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones.
WO2005062824A3 (fr) Composes anti-hypercholesterolemie
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
BR0312934A (pt) Derivados de 8-hidróxi quinolina
TW200740760A (en) Malonamide derivatives
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
WO2007087151A3 (fr) Méthode de traitement d'un dysfonctionnement cognitif
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
WO2006138163A3 (fr) Composes anti-hypercholesterolemiques
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser